Lisata Therapeutics, Inc. (NASDAQ:LSTA – Free Report) – Stock analysts at HC Wainwright issued their Q2 2025 earnings estimates for shares of Lisata Therapeutics in a research report issued to clients and investors on Wednesday, June 18th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.66) per share for the quarter. The consensus estimate for Lisata Therapeutics’ current full-year earnings is ($2.66) per share. HC Wainwright also issued estimates for Lisata Therapeutics’ Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($2.79) EPS, FY2026 earnings at ($1.25) EPS, FY2027 earnings at ($1.33) EPS and FY2028 earnings at ($1.17) EPS.
Lisata Therapeutics (NASDAQ:LSTA – Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.02).
Lisata Therapeutics Stock Down 3.6%
Institutional Trading of Lisata Therapeutics
An institutional investor recently bought a new position in Lisata Therapeutics stock. Citadel Advisors LLC purchased a new position in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 23,273 shares of the company’s stock, valued at approximately $69,000. Citadel Advisors LLC owned 0.28% of Lisata Therapeutics at the end of the most recent quarter. Institutional investors own 8.94% of the company’s stock.
About Lisata Therapeutics
Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.
Read More
- Five stocks we like better than Lisata Therapeutics
- Asset Allocation Strategies in Volatile Markets
- Microsoft Stock Holds Steady as AI Drives Workforce Shift
- What is a Low P/E Ratio and What Does it Tell Investors?
- D-Wave Goes International With South Korea Partnership
- What is MarketRank™? How to Use it
- Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.